Hunter Perkins Capital Management, LLC Mersana Therapeutics, Inc. Transaction History
Hunter Perkins Capital Management, LLC
- $431 Million
- Q1 2025
A detailed history of Hunter Perkins Capital Management, LLC transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Hunter Perkins Capital Management, LLC holds 10,000 shares of MRSN stock, worth $3,300. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,000
Previous 10,000
-0.0%
Holding current value
$3,300
Previous $14,000
78.57%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding MRSN
# of Institutions
115Shares Held
98MCall Options Held
16.3KPut Options Held
13K-
Nextech Invest Ag12.1MShares$3.98 Million3.22% of portfolio
-
Nextech Invest, Ltd. Zurich, V812.1MShares$3.98 Million0.97% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA8.66MShares$2.86 Million0.99% of portfolio
-
Black Rock Inc. New York, NY8.38MShares$2.77 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.38MShares$2.76 Million0.0% of portfolio
About Mersana Therapeutics, Inc.
- Ticker MRSN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,169,296
- Market Cap $32.1M
- Description
- Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...